Rheumatic fever secondary prevention

Revision as of 20:01, 19 October 2015 by Anthony Gallo (talk | contribs)
Jump to navigation Jump to search

Rheumatic fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rheumatic Fever from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Jones Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Rheumatic fever secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rheumatic fever secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rheumatic fever secondary prevention

CDC on Rheumatic fever secondary prevention

Rheumatic fever secondary prevention in the news

Blogs on Rheumatic fever secondary prevention

Directions to Hospitals Treating Rheumatic fever

Risk calculators and risk factors for Rheumatic fever secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Lance Christiansen, D.O.; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Anthony Gallo, B.S. [4]

Overview

Secondary prevention strategies following rheumatic fever include antibiotic prophylaxis immediately after the antibiotic course in treatment of rheumatic fever. Duration of prophylactic treatment varies with degree of cardiac damage secondary to rheumatic fever.

Secondary Prevention

Secondary prevention strategies following rheumatic fever include antibiotic prophylaxis immediately after the antibiotic course in treatment of rheumatic fever. Duration of prophylactic treatment varies with degree of cardiac damage secondary to rheumatic fever. If the patient or their household contacts develop streptococcal pharyngitis during the prophylactic period, they should be evaluated and treated promptly.

Providing prophylactic therapy to individuals who have had rheumatic fever with monthly injections of benzathine penicillin G or oral penicillin V decreases the frequency of recurrent Streptococcus pyogenes infections and recurrent rheumatic fever episodes. It is estimated that the recurrence rate of rheumatic fever is decreased about 85% by providing prophylactic penicillin therapy.

Alternatives to benzathine penicillin G are available, although they are less effective and require careful monitoring. These include:[1][2]

Patient Alternative Secondary Preventive Thearpy
Refuses intramuscular benzathine penicillin G Oral penicillin
Allergic to penicillin A non beta-lactam antimicrobial (e.g., erythromycin)
Pregnant Penicillin prophylaxis should continue for the duration of pregnancy, as there is no evidence of teratogenicity. Erythromycin is also considered safe in pregnancy.
Anticoagulated Benzathine penicillin G injections should continue unless there is evidence of uncontrolled bleeding, or the international normalized ratio is outside the defined therapeutic window

Recurrence of rheumatic fever is higher among patients receiving oral prophylaxis than those receiving intramuscular benzathine penicillin G. This may be attributed to patient compliance.[3].

Secondary prophylaxis for 1 year among patients with post streptococcal reactive arthritis (PSRA) is recommended by some patients have been observed to develop valvular heart disease.[4][5]

Antimicrobial Regimen

  • Secondary prevention of rheumatic fever[6]

2008 and Incorporated 2006 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease (DO NOT EDIT) [7]

Secondary Prevention (DO NOT EDIT) [7]

Class I

"1. Patients who have had rheumatic fever with or without carditis (including patients with MS) should receive prophylaxis for recurrent rheumatic fever.(Level of Evidence: B)"


References

  1. RF/RHD Guideline Development Working Group of the National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia: an evidence-based review. Sydney (Australia): National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand; 2006 Jun
  2. http://www.guideline.gov/content.aspx?id=10369
  3. FEINSTEIN AR, WOOD HF, EPSTEIN JA, TARANTA A, SIMPSON R, TURSKY E (1959). "A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. II. Results of the first three years of the study, including methods for evaluating the maintenance of oral prophylaxis". N Engl J Med. 260 (14): 697–702. doi:10.1056/NEJM195904022601405. PMID 13644570.
  4. Ahmed S, Ayoub EM, Scornik JC, Wang CY, She JX (1998). "Poststreptococcal reactive arthritis: clinical characteristics and association with HLA-DR alleles". Arthritis Rheum. 41 (6): 1096–102. doi:10.1002/1529-0131(199806)41:6<1096::AID-ART17>3.0.CO;2-Y. PMID 9627020.
  5. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST; et al. (2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics". Circulation. 119 (11): 1541–51. doi:10.1161/CIRCULATIONAHA.109.191959. PMID 19246689.
  6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): e57–185. doi:10.1016/j.jacc.2014.02.536. PMID 24603191.
  7. 7.0 7.1 Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter |month= ignored (help)

Template:WH Template:WS